ZNF683 and non-small cell lung carcinoma: In NSCLC, we characterized CD8-ZNF683-T1 (LEF+/TBX21-) and CD8-ZNF683-T2 (LEF+/TBX21+) from CD8-ZNF683 (Figure 6a).